70 related articles for article (PubMed ID: 29164976)
1. Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
Shen Y; Best OG; Mulligan SP; Christopherson RI
Leuk Lymphoma; 2018 Aug; 59(8):1927-1937. PubMed ID: 29164976
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M
Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279
[No Abstract] [Full Text] [Related]
3. The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia.
Cerreto M; Foà R; Natoni A
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958334
[TBL] [Abstract][Full Text] [Related]
4. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
5. Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity.
Weber ANR; Bittner Z; Liu X; Dang TM; Radsak MP; Brunner C
Front Immunol; 2017; 8():1454. PubMed ID: 29167667
[TBL] [Abstract][Full Text] [Related]
6.
Coulter EM; Pepper A; Mele S; Folarin N; Townsend W; Cuthill K; Phillips EH; Patten PEM; Devereux S
Haematologica; 2018 Mar; 103(3):497-505. PubMed ID: 29242301
[TBL] [Abstract][Full Text] [Related]
7. Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
Xu Y; Fahrbach K; Dorman E; Baculea S; Côté S; Sanden SV; Diels J
J Comp Eff Res; 2018 May; 7(5):421-441. PubMed ID: 29210593
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature.
Annalisa A; Simona B; Lara P; Elena T; Filippo MC; Angela R; Luca Z; Daniele V
Leuk Res Rep; 2017; 8():21-23. PubMed ID: 29234595
[TBL] [Abstract][Full Text] [Related]
9. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
[TBL] [Abstract][Full Text] [Related]
10. How should we sequence and combine novel therapies in CLL?
Davids MS
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
[TBL] [Abstract][Full Text] [Related]
11. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.
Gaidano G; Rossi D
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):329-337. PubMed ID: 29222275
[TBL] [Abstract][Full Text] [Related]
12. New Indication for Ibrutinib.
Aschenbrenner DS
Am J Nurs; 2017 Dec; 117(12):22. PubMed ID: 29189239
[No Abstract] [Full Text] [Related]
13. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
Greenwell IB; Ip A; Cohen JB
Oncology (Williston Park); 2017 Nov; 31(11):821-8. PubMed ID: 29179250
[TBL] [Abstract][Full Text] [Related]
14. Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib.
Jiang F; Verma P
Ann Allergy Asthma Immunol; 2018 Mar; 120(3):324-325. PubMed ID: 29174859
[No Abstract] [Full Text] [Related]
15. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
16. How I treat CLL patients with ibrutinib.
Brown JR
Blood; 2018 Jan; 131(4):379-386. PubMed ID: 29255067
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
Jamroziak K; Szymczyk A; Hus M; Wojciechowska M; Knopinska-Posłuszny W; Hołojda J; Hałaburda K; Warzocha K; Iskierka-Jażdżewska E
Eur J Haematol; 2018 Apr; 100(4):389-391. PubMed ID: 29243346
[No Abstract] [Full Text] [Related]
18. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
19. Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia.
Mayer RL; Schwarzmeier JD; Gerner MC; Bileck A; Mader JC; Meier-Menches SM; Gerner SM; Schmetterer KG; Pukrop T; Reichle A; Slany A; Gerner C
Mol Cell Proteomics; 2018 Feb; 17(2):290-303. PubMed ID: 29196338
[TBL] [Abstract][Full Text] [Related]
20. "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
Chapiro E; Lesty C; Gabillaud C; Durot E; Bouzy S; Armand M; Le Garff-Tavernier M; Bougacha N; Struski S; Bidet A; Laharanne E; Barin C; Veronese L; Prié N; Eclache V; Gaillard B; Michaux L; Lefebvre C; Gaillard JB; Terré C; Penther D; Bastard C; Nadal N; Fert-Ferrer S; Auger N; Godon C; Sutton L; Tournilhac O; Susin SA; Nguyen-Khac F;
Am J Hematol; 2018 Mar; 93(3):375-382. PubMed ID: 29194741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
